Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07062848 · ClinicalTrials.gov registry record
An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.
A clinical trial of Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Yale University.
- Active
- Registry status
- 1,500,000
- Enrollment target
- 11
- Study locations
NCT07062848: Active study of Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Yale University.
NCT07062848 is a study of Transthyretin (TTR) Amyloid Cardiomyopathy that is active but no longer recruiting, run by Yale University. The registered enrollment target is 1,500,000 participants. The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07062848, a study of Transthyretin (TTR) Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 1,500,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a fully federated deployment of an artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AI Toolkit for ATTR-CM Diagnosis
Study Locations (11)
Texas
- UT Southwestern Medical Center - Dallas
- Houstin Methodist - Houston
California
- University of California - San Francisco (UCSF) Health - San Francisco
Connecticut
- Yale New Haven Health System - New Haven
Michigan
- Henry Ford Health - Detroit
New York
- Mount Sinai - New York
North Carolina
- Duke Health - Durham
Oregon
- Providence Health - Tigard
South Carolina
- Medical University of South Carolina (MUSC) Health - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500,000 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2027-01 |
What the registry record for NCT07062848 still lists
NCT07062848 is an observational study that tracks outcomes without assigning an intervention. Its 1,500,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Transthyretin (TTR) Amyloid Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which AI Toolkit for ATTR-CM Diagnosis is the first listed.
NCT07062848 lists 11 locations in 10 states (Texas, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07062848 about?
NCT07062848 is a clinical study titled "An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.". This is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a fully federated deployment of an artificial intelligence (AI) toolkit of ...
What is the current status of trial NCT07062848?
This trial is currently active not recruiting. The enrollment target is 1,500,000 participants. The study started on 2025-01-24. Estimated completion is 2027-01.
What conditions does trial NCT07062848 study?
This clinical trial studies the following conditions: Transthyretin (TTR) Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT07062848?
The interventions under investigation include: AI Toolkit for ATTR-CM Diagnosis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07062848?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07062848 being conducted?
This trial has 11 study locations across California, Connecticut, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin (TTR) Amyloid Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI